Evaluation of a New ‘Mix-In’ Style Glycomacropeptide-Based Protein Substitute for Food and Drinks in Patients with Phenylketonuria and Tyrosinemia

Author:

Delsoglio Marta1,Capener Rebecca1,MacDonald Anita2,Daly Anne2ORCID,Ashmore Catherine2,Donald Sarah3,Gaff Lisa3,VanDorp Louise4,Skeath Rachel4,Ellerton Charlotte5,Newby Camille6,Dunning Georgina6,Dale Clare7,Hunjan Inderdip8,White Lucy9,Allen Heather9,Hubbard Gary P.1,Stratton Rebecca J.110ORCID

Affiliation:

1. Research and Innovation, Nutricia Ltd., White Horse Business Park, Trowbridge BA14 0XQ, UK

2. Dietetic Department, Birmingham Children’s Hospital, Birmingham B4 6NH, UK

3. Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK

4. Great Ormond Street Hospital for Children NHS Foundation Trust, London WC1N 3JH, UK

5. University College London Hospitals NHS Foundation Trust, London WC1N 3BG, UK

6. Bristol University Hospitals NHS Foundation Trust, Bristol BS1 3NU, UK

7. Queen Elizabeth Hospital, Birmingham B15 2TH, UK

8. Bradford Teaching Hospitals, NHS Foundation Trust, Bradford BD5 0NA, UK

9. Sheffield Children’s NHS Foundation Trust, Sheffield S10 2TH, UK

10. Faculty of Medicine, University of Southampton, Southampton SO16 6YD, UK

Abstract

(1) Background: Poor palatability, large volume, and lack of variety of some liquid and powdered protein substitutes (PSs) for patients with phenylketonuria (PKU) and tyrosinemia (TYR) can result in poor adherence. This study aimed to evaluate a new unflavoured, powdered GMP-based PS designed to be mixed into drinks, foods, or with other PSs, in patients with PKU and TYR. (2) Methods: Paediatric and adult community-based patients were recruited from eight metabolic centres and prescribed ≥1 sachet/day (10 g protein equivalent (PE)) of the Mix-In-style PS over 28 days. Adherence, palatability, GI tolerance, and metabolic control were recorded at baseline and follow-up. Patients who completed at least 7 days of intervention were included in the final analysis. (3) Results: Eighteen patients (3–45 years, nine males) with PKU (n = 12) and TYR (n = 6) used the Mix-In-style PS for ≥7 days (mean 26.4 days (SD 4.6), range 11–28 days) alongside their previous PS, with a mean intake of 16.7 g (SD 7.7) PE/day. Adherence was 86% (SD 25), and GI tolerance was stable, with n = 14 experiencing no/no new symptoms and n = 3 showing improved symptoms compared to baseline. Overall palatability was rated satisfactory by 78% of patients, who successfully used the Mix-In-style PS in various foods and drinks, including smoothies, squash, and milk alternatives, as a top-up to meet their protein needs. There was no concern regarding safety/metabolic control during the intervention. (4) Conclusions: The ‘Mix-In’-style PS was well adhered to, accepted, and tolerated. Collectively, these data show that providing a flexible, convenient, and novel format of PS can help with adherence and meet patients’ protein needs.

Funder

Nutricia Ltd.

Publisher

MDPI AG

Subject

Food Science,Nutrition and Dietetics

Reference47 articles.

1. Chakrapani, A., Gissen, P., and McKiernan, P. (2012). Inborn Metabolic Diseases: Diagnosis and Treatment, Springer.

2. Phenylalanine hydroxylase deficiency: Diagnosis and management guideline;Vockley;Genet. Med.,2014

3. Protein intake affects phenylalanine requirements and growth of infants with phenylketonuria;Acosta;Acta Paediatr.,1994

4. Protein requirements in infants and children: A longitudinal study of children treated for phenylketonuria;Kindt;Am. J. Clin. Nutr.,1983

5. Nutritional Management of Phenylketonuria;MacLeod;Ann. Nestle,2010

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3